title: The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells.
abstract: Somatostatin receptors (sst1-5) are present in different types of tumors, where they inhibit key cellular processes such as proliferation and invasion. Although ssts are densely expressed in breast cancer, especially sst2, their role and therapeutic potential remain uncertain. Recently, we identified a new truncated sst5 variant, sst5TMD4, which is related to the abnormal response of certain pituitary tumors to treatment with somatostatin analogs. Here, we investigated the possible role of sst5TMD4 in breast cancer. This study revealed that sst5TMD4 is absent in normal mammary gland, but is abundant in a subset of poorly differentiated human breast tumors, where its expression correlated to that of sst2. Moreover, in the MCF-7 breast cancer model cell, sst5TMD4 expression increased malignancy features such as invasion and proliferation abilities (both in cell cultures and nude mice). This was likely mediated by sst5TMD4-induced increase in phosphorylated extracellular signal-regulated kinases 1 and 2 and p-Akt levels, and cyclin D3 and Arp2/3 complex expression, which also led to mesenchymal-like phenotype. Interestingly, sst5TMD4 interacts physically with sst2 and thereby alters its signaling, enabling disruption of sst2 inhibitory feedback and providing a plausible basis for our findings. These results suggest that sst5TMD4 could be involved in the pathophysiology of certain types of breast tumors.
authors.affiliation: Department of Cell Biology, Physiology and Immunology, University of Córdoba, Reina Sofía University Hospital, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), and CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Córdoba, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Durán-Prado
authors.forename: M D
authors.initials: MD
authors.lastname: Gahete
authors.forename: M
authors.initials: M
authors.lastname: Hergueta-Redondo
authors.forename: A J
authors.initials: AJ
authors.lastname: Martínez-Fuentes
authors.forename: J
authors.initials: J
authors.lastname: Córdoba-Chacón
authors.forename: J
authors.initials: J
authors.lastname: Palacios
authors.forename: F
authors.initials: F
authors.lastname: Gracia-Navarro
authors.forename: G
authors.initials: G
authors.lastname: Moreno-Bueno
authors.forename: M M
authors.initials: MM
authors.lastname: Malagón
authors.forename: R M
authors.initials: RM
authors.lastname: Luque
authors.forename: J P
authors.initials: JP
authors.lastname: Castaño
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D014644:Genetic Variation; D006801:Humans; D048369:MAP Kinase Kinase 1 / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D009361:Neoplasm Invasiveness; D009368:Neoplasm Transplantation; D051058:Oncogene Protein v-akt / Q000378:metabolism; D010766:Phosphorylation; D011379:Prognosis; D017481:Receptors, Somatostatin / Q000235:genetics*; D013004:Somatostatin / Q000502:physiology
chemical_list: D017481:Receptors, Somatostatin; D013004:Somatostatin; D051058:Oncogene Protein v-akt; D048369:MAP Kinase Kinase 1